Table 1.
Demographics and baseline characteristics
| Vildagliptin group (n = 55) | Sulfonylurea group (n = 42) | |
| Age (yr) | 51.0 ± 8.8 | 50.9 ± 9.1 |
| ≥ 65 yr | 4 (7.3) | 4 (9.5) |
| Weight, kg | 69.1 ± 10.9 | 67.4 ± 10.0 |
| Height, cm | 159.7 ± 8.1 | 158.4 ± 9.8 |
| HbA1c, % (mmol/mol) | 8.75 ± 1.27 (72.10 ± 13.90) | 8.64 ± 1.57 (70.92 ± 17.14) |
| HbA1c < 7.0% (< 53.0 mmol/mol) | 3 (5.5) | 6 (14.3) |
| FPG, mg/dL | 140.2 ± 42.0 | 162.1 ± 48.2 |
| PPG, mg/dL | 212.2 ± 52.2 | 220.6 ± 54.0 |
| Patients receiving metformin, n (%) | 38 (69.1) | 30 (71.4) |
| Mean doses of sulfonylureas, mg/d | ||
| Glibenclamide (n = 7) | - | 10 |
| Gliclazide (n = 10) | - | 106 |
| Glimepiride (n = 23) | - | 4.2 |
| Glipizide (n = 2) | - | 10 |
Data are shown as mean ± SD or n (%), unless otherwise stated. Vildagliptin group: Patients receiving vildagliptin ± metformin; Sulfonylurea group: Patients receiving sulfonylurea ± metformin; FPG: Fasting plasma glucose; PPG: Postprandial plasma glucose.